SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial

In this 56-week, randomized, double-blind, US-based multicenter trial (NCT02963935) we investigated the effects of liraglutide 3.0 mg vs placebo, as adjunct to intensive behavior therapy (IBT) (i.e. reduced calorie intake, increased physical activity [max target: 250 min/week], and 23 counseling ses...

Descripción completa

Detalles Bibliográficos
Autores principales: Wadden, Thomas, Shaw Tronieri, Jena, Sugimoto, Daniel, Lund, Michael, Auerbach, Pernille, Jensen, Camilla, Rubino, Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552061/
http://dx.doi.org/10.1210/js.2019-SAT-099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552061/
http://dx.doi.org/10.1210/js.2019-SAT-099

Ejemplares similares